Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
Authors
Keywords
-
Journal
International Journal of Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-07
DOI
10.1007/s10147-021-02006-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting FLT3 mutations in AML: review of current knowledge and evidence
- (2019) Naval Daver et al. LEUKEMIA
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
- (2019) Takeshi Takahashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia
- (2019) Masahiro Sakaguchi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
- (2018) Chezi Ganzel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clinical Profile of Gilteritinib in Japanese Patients with Relapsed/Refractory AML: an Open-Label Phase 1 Study
- (2018) Kensuke Usuki et al. CANCER SCIENCE
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
- (2017) M Wattad et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
- (2016) Lauren Y. Lee et al. BLOOD
- Type distribution of myeloid leukemia from Cancer Incidence in Five Continents Vol. X
- (2016) Mariko Niino et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
- (2015) C C Smith et al. LEUKEMIA
- Inhibition of c-Kit by tyrosine kinase inhibitors
- (2014) A. Galanis et al. HAEMATOLOGICA
- Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
- (2014) R Kihara et al. LEUKEMIA
- Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia Study Group
- (2012) Shuichi Miyawaki INTERNATIONAL JOURNAL OF HEMATOLOGY
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
- (2011) P Chevallier et al. LEUKEMIA
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started